Cocrystal Pharma reports FY2023 net loss of $18.0M; pipeline progress on influenza and COVID-19 programs

Cocrystal Pharma, Inc.

Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
Cash at Dec 31, 2023: $26.4M, down from $37.1M; net cash used in ops $14.7M.
FDA provided Pre-IND feedback clarifying requirements for Phase 2b trial of oral CC-42344 for influenza A.
Expect topline data in 2024 from Phase 2a human challenge study with CC-42344 and Phase 1 study with CDI-988.
Plan to initiate Phase 1 study of inhaled CC-42344 in 2024 as influenza treatment/prophylactic.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Cocrystal Pharma, Inc. reported financial results for the 12 months ended December 31, 2023.

Period: the 12 months ended December 31, 2023
Result: reported results

Exact text from the filing

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.